Nektar and Takeda team up to explore anti-cancer potential of NKTR-214
Seeking Alpha
Published May 22, 2017 11:35AM ET
Nektar and Takeda team up to explore anti-cancer potential of NKTR-214
- Nektar Therapeutics (NKTR +0.3%) and Takeda Pharmaceutical Company (OTCPK:TKPYY) enter into a research collaboration to explore the cancer-fighting potential of the combination of Nektar's NKTR-214 with five Takeda compounds.
- Under the terms of the partnership, the companies will the costs of preclinical studies and each will supply their respective compounds. Both will retain global commercial rights to their candidates.
- NKTR-214 stimulates the immune system by targeting CD122-specific receptors found on the surface of certain immune cells which stimulates their proliferation.
- Now read: Takeda Takes A Plunge Into The Fringes Of Cell Therapy
Original article
Get The News You Want
Written By: Seeking Alpha
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.